Vancouver, British Columbia/ACCESSWIRE/6 July 2022/ Clairvoyant Therapeutics, a Canadian biotechnology company, is pleased to announce that it has started the first of 15 sites planned for CLARITY, the company’s Phase II clinical trial investigating psilocybin in the treatment of alcohol use disorder (AUD) (formerly known as AUD). with alcohol addiction).
CLARITY is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of 25 mg synthetic psilocybin in combination with Enhanced Stimulant Therapy (MET). CLARITY has been approved in Canada and submitted for regulatory approval in selected EU countries for phase II clinical trials.
“We are excited to begin our Phase 2 clinical trial,” said Damian Kettlewell, co-founder and CEO of Clairvoyant. “At Clairvoyant, we hope the results of this clinical trial will support the company’s new anesthetic treatment model to address the significant unmet medical needs of AUD patients.”
The remaining 15 sites are in an advanced stage of negotiations. These sites are located in the major centers of Canada and Europe. The large number of drug trial sites reflects Clairvoyant’s goal of being the first company worldwide to register psilocybin as a therapeutic product for the treatment of AUD patients.
About alcohol use disorder
According to the World Health Organization, 283 million people aged 15 years and over are at risk of developing an alcohol use disorder.[i] Globally, deaths from alcohol consumption are higher than deaths from diseases such as tuberculosis, HIV/AIDS and diabetes.[i]
About Psilocybin and CLARITY TREATMENT
Psilocybin is the pharmaceutical agent in some mushrooms known to cause a temporary narcotic state. It was first purified in the 1950s. After thousands of registered administrations, no potential addiction or abuse of psilocybin has been identified. In the CLARITY Experience, people are accompanied on their drug therapy journey by highly trained therapists who have been certified under Clairvoyant’s Professional and Ethical Certification Program.
Clairvoyant Therapeutics is a Canadian biotechnology company that is changing the face of psychedelic therapy with a clinical marketing strategy designed to enable psilocybin therapy in the EU, UK and Canada for the treatment of patients with alcohol use disorder (AUD) starting in 2026.
The company’s exceptional team, with a proven track record of clinical trials and deep drug development expertise, has made Clairvoyant the world’s most advanced company in developing psilocybin therapy for AUD.
Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to strike a balance between profit and purpose and is B Corporation’s outstanding certification. Clairvoyant is a member of Life Science BC and the Biotechnology Innovation Organization (BIO).
Learn more at www.clairvoyantrx.com and follow the company on LinkedIn and Twitter.
for more information:
[i] World Health Organization. Global alcohol action plan 2022-2030 to enhance implementation of the global strategy to reduce harmful use of alcohol first draft. June 2021
source: clairvoyants treatment
View the source version on accesswire.com: